Abstract: Pemphigus vulgaris is an autoimmune disease characterized by suprabasal blisters with acantholysis, which has a fatal course in a large number of untreated patients. Systemic corticosteroid therapy is considered fi rst-line therapy. Adjuvant treatment with the goal of sparing corticosteroids include, among others, dapsone. This drug is not without side effects and its use requires clinical and laboratory control. We present a patient with PV initially managed with suboptimal dose of prednisone, evolving into drug-induced hepatitis after introduction of dapsone.
INTRODUCTION
Pemphigus vulgaris (PV) is an autoimmune disease characterized by blisters that may occur in the mucosa or in other areas of the skin. The characteristic histopathological fi nding of PV are suprabasal blisters with acantholysis. 1 Glucocorticoids are considered the fi rst-line treatment and are used to reduce the synthesis of autoantibodies. The addition of a second-line therapy is indicated to increase the effi cacy and reduce collateral effects of corticotherapy, as well as manage relapses during its gradual withdrawal. 2 The adjuvant therapy includes azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil, intravenous immunoglobulin and dapsone. 3 A patient with PV is presented, initially treated with a subdose of systemic corticotherapy which evolved to drug-induced hepatitis after introduction of dapsone.
CASE REPORT
Female patient of african-descent, 50 years old, came to the outpatient clinic complaining of a single fi ve-month-old bullous lesion in the oral mucosa, which evolved to erosion and onset of similar cutaneous lesions in other sites. At the examination, ulcerated crusty lesions were found on the face, scalp, trunk, back and upper limbs, some with honey-colored crusts.
She had been previously treated at another clinic with topical antifungals without improvement, followed by prednisone 20mg/day with slight improvement, which after four months was associated with dapsone 100mg/day as adjuvant therapy.
At our service, under the diagnostic hypothesis of PV, we performed the histopathological study which showed infl ammatory suprabasal acantholytic bullous dermatitis with involvement of pilosebaceous follicle, compatible with PV (Figures 1 and 2 ). Our option was to increase prednisone to 80mg/day, with gradual reduction after clinical improvement.
Two weeks after starting therapy with prednisone in its immunosuppression dose and six weeks taking dapsone, the patient reported clinical improvement and denied onset of new lesions. Laboratory control revealed elevation of glutamic oxaloacetic transaminase (GOT 40 U/L) glutamic-pyruvic transaminase (GPT 76 U/L), gamma-glutamyl transferase (GGT 151 U/L) and alkaline phosphatase (ALP 117 U/L), in addition to leukocytosis (17.300/mm3); dapsone was suspended. The following week, she returned complaining of itching, dark urine, acholic feces and jaundice when new control showed signifi cant elevation of aminotransferases (AST 410 U/L, ALT 622 U/L), bile canalicular enzymes (ALP 361 U/L GGT 1265 U/L), direct bilirubin (BD 4.0 mg/dl) and indirect bilirubin (BI 3.7 mg/dl). She was then hospitalized and serology for viral hepatitis was requested, which resulted negative. A total abdominal ultrasonography revealed no abnormalities. The blood levels of liver enzymes and bilirubin during dapsone use and after withdrawal are shown in fi gures 3 and 4. Thirteen weeks after suspension of dapsone, with decreasing doses of corticotherapy until the current dose of prednisone 30mg/day, the patient presented clinical improvement: only small ulcerated crusty areas on the scalp and absence of new lesions. Residual hyperchromic macules were also noted on the face, trunk, back and upper limbs ( Figure 5 ).
DISCUSSION
Systemic corticotherapy is essential in the management of pemphiguses. For PV, the initial dose is 1-2 mg/kg/day. The reduction of the corticoid must be started after complete remission of the cutaneous condition and about 1-2 weeks without the onset of new lesions. The dose is reduced by 10mg/week until 30mg/day is achieved and following that the reduction should be 5-10 mg/month, obtaining the dose of 10mg/day. From this dose, withdrawal occurs with decrease of 2.5 mg every 1-2 months according to clinical course of the disease. Treatment may be suspended after 1 year of low daily doses on alternate days, without the onset of new lesions. 4 For PV, dapsone is appropriate as an adjuvant to corticotherapy in the maintenance phase of the disease. 5, 6 Clinical improvement, in general, happens in 2-3 weeks from the beginning of treatment, leading to sharp reduction or even corticoid suspension within 1-3 months. Dapsone acts by diminishing paraminobenzoic acid to folic acid conversion, preventing the migration of polymorphonuclear cells by inhibiting lysosomal enzymatic activity, interfering with the leucocitary cytotoxic system or preventing cellular response to chemotactic stimuli. 7 There is evidence of dapsone effi cacy (71% to 83.3%) in the adjuvant treatment with topical or oral corticosteroids in patients with pemphiguses. 8 Collateral effects of dapsone may be classifi ed into idiosyncratic and dose-dependent. Among the idiosyncratic ones there is the rare dapsone hypersensitivity syndrome, characterized by fever, lymphadenopathy, erythematous cutaneous eruptions and occasionally hepatic involvement. Dose-dependent effects encompass hemolysis and methemoglobinemia. 7 A study in tertiary centers showed that this drug was the most common cause of acquired methemoglobinemia, responsible for 42% of the cases. 9 Methemoglobinemia is not caused by the drug itself, but by its metabolite, hydroxylamine. 8 A link between development of drug-induced hepatitis and dapsone has been suspected. Complete blood count must be monitored monthly in the fi rst six months of use and renal and liver function must be verifi ed quarterly for toxicity research. 2 The interval between the initiation of treatment and the onset of hepatitis varies from two to seven weeks. Hepatocellular and cholestatic reactions may occur, the latest being the most common mechanism of the lesion and characterized by the elevation of alkaline phosphatase and transaminases. The hepatocellular lesion is characterized by elevation of transaminases and the lesion mechanism occurs by hepatotoxicity and hypersensitivity reaction. 10 The patient of the present case developed drug-induced hepatitis with cholestatic pattern by dapsone, due to the time she started using it, laboratory alterations found and exclusion of other hepatopathology causes.
Therefore, in this clinical case, the use of dapsone as corticoid-sparing drug is reported for PV, a disease of signifi cant morbimortality, and the occurrence of drug-induced hepatitis by this drug, emphasizing the relevance of laboratory control during its use, aiming to prevent undesirable collateral effects, deleterious if not detected early.❑
